MDS 2023 | SINTRA-REV update: early lenalidomide treatment in non-transfusion dependent del(5q) LR-MDS
Maria Diez Campelo, MD, PhD, University of Salamanca, University Hospital Salamanca, gives a brief update on SINTRA-REV (NCT01243476), a Phase III study evaluating early treatment with lenalidomide vs placebo in non-transfusion dependent patients with low-risk myelodysplastic syndromes (MDS) with deletion 5q. Overall the study showed that this treatment did not promote clonal evolution and was a tolerable approach in this patient population. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
